Latest Articles

Publication Date
All News Scientific
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0

Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0

Published: Oct. 20, 2025, 3:54 p.m.
Read Full Article
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E - PharmiWeb.com

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in E PharmiWeb.com

Published: Oct. 20, 2025, 3:02 p.m.
Read Full Article
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU - The Manila Times

EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU The Manila Times

Published: Oct. 20, 2025, 12:36 p.m.
Read Full Article
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 20, 2025, noon
Read Full Article
Could this lakeside mansion set a new Ballarat price record? - Herald Sun

Could this lakeside mansion set a new Ballarat price record? Herald Sun

Published: Oct. 20, 2025, 4:53 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - BioSpace

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer BioSpace

Published: Oct. 20, 2025, 4:42 a.m.
Read Full Article
Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region - Cureus

Catamenial Pneumothorax Without Thoracic Endometriosis: A Case Report From the Gulf Cooperation Council (GCC) Region Cureus

Published: Oct. 19, 2025, 12:43 a.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti - PharmiWeb.com

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti PharmiWeb.com

Published: Oct. 18, 2025, 1:03 p.m.
Read Full Article
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer - Lelezard

Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer Lelezard

Published: Oct. 18, 2025, 12:47 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!